In adults, proton therapy is the preferred treatment for complicated head and neck malignancies, large base of skull tumors, esophageal cancer, localized recurrent cancer, and certain ocular tumors and is becoming the standard for adult patients with low-grade gliomas and meningiomas, and breast, GI, and prostate cancers. Research and clinical trials with proton therapy will drive innovations in cancer treatment and enhance Duke’s impact across multiple missions, including clinical care, research, and education,” said Mary E. Klotman, MD, executive vice president for health affairs at Duke University and dean of Duke University School of Medicine.